106 related articles for article (PubMed ID: 35461118)
21. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
22. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
23. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
[TBL] [Abstract][Full Text] [Related]
24. Patient Response Trajectories in Major Depressive Disorder.
Larsen KG; Kennedy SH; Reines EH; Thase ME
Psychopharmacol Bull; 2020 Sep; 50(4):8-28. PubMed ID: 33012870
[TBL] [Abstract][Full Text] [Related]
25. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
[TBL] [Abstract][Full Text] [Related]
27. Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report.
Ballester PL; Suh JS; Nogovitsyn N; Hassel S; Strother SC; Arnott SR; Minuzzi L; Sassi RB; Lam RW; Milev R; Müller DJ; Taylor VH; Kennedy SH; Frey BN;
Neuroimage Clin; 2021; 32():102864. PubMed ID: 34710675
[TBL] [Abstract][Full Text] [Related]
28. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
30. Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report.
Husain MI; Foster JA; Mason BL; Chen S; Zhao H; Wang W; Rotzinger S; Rizvi S; Ho K; Lam R; MacQueen G; Milev R; Frey BN; Müller D; Turecki G; Jha M; Trivedi M; Kennedy SH
CNS Spectr; 2023 Dec; 28(6):739-746. PubMed ID: 37218291
[TBL] [Abstract][Full Text] [Related]
31. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
32. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
Allen TA; Lam RW; Milev R; Rizvi SJ; Frey BN; MacQueen GM; Müller DJ; Uher R; Kennedy SH; Quilty LC
Psychol Med; 2019 Jul; 49(10):1629-1638. PubMed ID: 30220263
[TBL] [Abstract][Full Text] [Related]
33. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
34. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
Moore N; Verdoux H; Fantino B
Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
[TBL] [Abstract][Full Text] [Related]
35. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Lepola U; Wade A; Andersen HF
Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
[TBL] [Abstract][Full Text] [Related]
36. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
Gorman JM; Korotzer A; Su G
CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
[TBL] [Abstract][Full Text] [Related]
37. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
38. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
39. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
[TBL] [Abstract][Full Text] [Related]
40. Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study.
Horikoshi S; Miura I; Ichinose M; Yamamoto S; Ito M; Watanabe K; Kanno-Nozaki K; Kaneko H; Yabe H
Hum Psychopharmacol; 2019 May; 34(3):e2696. PubMed ID: 31044463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
